Share

    


In This Section

Home / Blurb / Discussion List

FDA Approves Pembrolizumab for First-Line Treatment of Metastatic Squamous NSCLC

Oct 31, 2018, 10:44 AM
URL:
On October 30, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck & Co., Inc.) in combination with carboplatin and either paclitaxel or nab-paclitaxel as first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC).

Read the full FDA press release here.

Posted 10/31/2018

Leave a comment